2022
Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
Coburn SB, Humes E, Lang R, Stewart C, Hogan BC, Gebo KA, Napravnik S, Edwards JK, Browne LE, Park LS, Justice AC, Gordon KS, Horberg MA, Certa JM, Watson E, Jefferson CR, Silverberg MJ, Skarbinski J, Leyden WA, Williams CF, Althoff KN. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States. JAMA Network Open 2022, 5: e2215934. PMID: 35671054, PMCID: PMC9175076, DOI: 10.1001/jamanetworkopen.2022.15934.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultCohort StudiesCOVID-19COVID-19 TestingCOVID-19 VaccinesHIV InfectionsHumansMaleProspective StudiesSARS-CoV-2United StatesConceptsBreakthrough infectionsFull vaccinationAdditional doseSARS-CoV-2 infection riskBreakthrough COVID-19 infectionsCOVID-19 breakthrough infectionsHIV viral load suppressionInfection riskSARS-CoV-2 infectionBreakthrough infection riskHigher CD4 countsViral load suppressionHIV viral loadAdditional vaccine dosesCOVID-19 vaccinationCOVID-19 infectionIntegrated health systemNon-Hispanic blacksCOVID-19 vaccineSARS-CoV-2Non-Hispanic whitesExpansion of RecommendationsCOVID-19 diagnosisAdvanced diseaseCD4 count
2020
Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus
Silverberg MJ, Leyden W, Hernández-Ramírez RU, Qin L, Lin H, Justice AC, Hessol NA, Achenbach CJ, D’Souza G, Engels EA, Althoff KN, Mayor AM, Sterling TR, Kitahata MM, Bosch RJ, Saag MS, Rabkin CS, Horberg MA, Gill MJ, Grover S, Mathews WC, Li J, Crane HM, Gange SJ, Lau B, Moore RD, Dubrow R, Neugebauer RS. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases 2020, 72: 1900-1909. PMID: 32785640, PMCID: PMC8315132, DOI: 10.1093/cid/ciaa1046.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeCD4 Lymphocyte CountHIVHIV InfectionsHumansNeoplasmsSarcoma, KaposiConceptsVirus-related cancersEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapyART initiationImmunodeficiency virusNorth American AIDS Cohort CollaborationART-naive PLWHEarly ART initiationAntiretroviral therapy initiationHIV transmission riskNon-Hodgkin lymphomaCancer registry linkageRisk of cancerMarginal structural modelsRace/ethnicityCohort CollaborationTherapy initiationChart reviewIncident cancerRegistry linkageViral hepatitisTime-dependent confoundingCancer groupViral etiologyCause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies
Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit F, Bonnet F, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier‐Pfistershammer K, Guest JL, Shepherd L, Teira R, Monforte A, del Amo J, Justice A, Costagliola D, Sterne J. Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies. International Journal Of Cancer 2020, 146: 3134-3146. PMID: 32003460, PMCID: PMC7187452, DOI: 10.1002/ijc.32895.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultFemaleFranceHodgkin DiseaseHumansLiver NeoplasmsLung NeoplasmsLymphoma, AIDS-RelatedMiddle AgedPrognosisSurvival RateUnited KingdomUterine Cervical NeoplasmsConceptsCause-specific mortalityCause of deathMortality rateGeneral populationLymphoma diagnosisCancer diagnosisHodgkin lymphoma diagnosisHIV-positive patientsCause-specific mortality ratesDiagnosis of cancerHIV cohortCohort studyCervical cancerSurvival outcomesLung cancerPLHIVSpecific cancersCancerCancer typesDiagnosisMortalityDeathSurvivalNADMAIDS
2018
Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation
Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR, investigators F. Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation. Journal Of The International AIDS Society 2018, 21: e25031. PMID: 29334197, PMCID: PMC5810321, DOI: 10.1002/jia2.25031.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCohort StudiesFemaleHumansLymphoma, Non-HodgkinMaleMiddle AgedPneumonia, PneumocystisTuberculosisConceptsAdjusted hazard ratioAntiretroviral therapy initiationAIDS mortalityAdjusted hazardCohort CollaborationTherapy initiationAntiretroviral Therapy Cohort CollaborationHIV-1 infectionTreatment-naïve adultsCause of deathMarginal structural modelsART initiationHIV protocolMetabolic deathHazard ratioChronic inflammationRisk factorsCoding CausesSubsequent deathMortalityAIDSCommon pathwayDeathUnmeasured confoundersCauseCommonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 102-109. PMID: 28991888, PMCID: PMC5720915, DOI: 10.1097/qai.0000000000001562.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS Dementia ComplexAIDS-Related Opportunistic InfectionsAlkynesAmericasAtazanavir SulfateBenzoxazinesCohort StudiesCyclopropanesDarunavirEuropeFemaleHIV Protease InhibitorsHumansLeukoencephalopathy, Progressive MultifocalLopinavirMaleMeningitis, CryptococcalMiddle AgedProspective StudiesReverse Transcriptase InhibitorsToxoplasmosisConceptsNucleoside reverse transcriptase inhibitor (NRTI) backboneReverse transcriptase inhibitor backboneHazard ratioNeurological conditionsInhibitor backbonePooled logistic modelCombined end pointRespective hazard ratiosProgressive multifocal leukoencephalopathyProspective cohort studyAntiretroviral therapy regimensHIV-positive individualsHIV-CAUSAL CollaborationIncidence of AIDSCART initiationHIV dementiaAntiretroviral therapyCART regimenCryptococcal meningitisMultifocal leukoencephalopathyClinical characteristicsCohort studyTherapy regimensAtazanavirLopinavir
2016
D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events
Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O’Bryan T, Rimland D, Justice AC, Agan BK, . D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLOS ONE 2016, 11: e0152588. PMID: 27088215, PMCID: PMC4835105, DOI: 10.1371/journal.pone.0152588.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsBiomarkersFemaleFibrin Fibrinogen Degradation ProductsHIVHIV InfectionsHumansInterleukin-6MaleProspective StudiesRisk FactorsSeroconversionViral LoadConceptsNon-AIDS diseasesNon-AIDS eventsD-dimer levelsHIV viral suppressionART initiationAntiretroviral therapyViral suppressionD-dimerInterleukin-6Time pointsUS Military HIV Natural History StudyMulticenter observational cohortMedian CD4 countIL-6 levelsMean percent increaseActive duty military personnelNatural history studiesDuty military personnelCD4 countHIV seroconversionHIV levelsMedian durationObservational cohortMedian timeExcess risk
2014
Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults
Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, Rimland D, Rodriguez-Barradas MC, Dubrow R, Park LS, Skanderson M, Shiels MS, Gange SJ, Gebo KA, Justice AC. Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults. Clinical Infectious Diseases 2014, 60: 627-638. PMID: 25362204, PMCID: PMC4318916, DOI: 10.1093/cid/ciu869.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseMyocardial infarctionUninfected adultsAge-associated eventsRenal diseaseHIV statusIncident diagnosisMean ageVeterans Aging Cohort StudyGreater riskCox proportional hazards modelAging Cohort StudyHuman immunodeficiency virusProportional hazards modelNon-AIDSUninfected veteransCohort studyMultivariate linear regression modelMedian ageComparison of risksImmunodeficiency virusAge-associated diseasesImportant confoundersHigh riskHazards model
2013
Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug useA Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care
Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care. AIDS And Behavior 2013, 17: 2293-2300. PMID: 23404097, PMCID: PMC3742414, DOI: 10.1007/s10461-013-0416-1.Peer-Reviewed Original ResearchConceptsViral load suppressionFeasibility outcomesPatient acceptabilityPatient comprehensionPlasma HIV RNADetectable viral loadViral load testsSingle-site studyEligible patientsHIV careHIV RNAART adherenceViral loadHIV transmissionOwn controlPatientsPatient workflowFinancial incentivesOutcomesCareDownstream costsIncentive sizeBiological outcomesAcceptabilityClinic
2012
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, Monforte A, Vehreschild JJ, Sterne J, Collaboration T. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal Of Epidemiology 2012, 41: 1807-1820. PMID: 23148105, PMCID: PMC3535877, DOI: 10.1093/ije/dys164.Peer-Reviewed Original ResearchConceptsCompleteness of ascertainmentHIV-positive patientsAntiretroviral therapyMortality rateAdult HIV-positive patientsPrevious AIDS diagnosisRates of AIDSAdjusted mortality rateMortality rate ratiosHigher mortality riskHigh mortality rateDiverse patient cohortCohort heterogeneityCohort CollaborationPatient characteristicsHIV treatmentAIDS diagnosisPatient cohortAdjusted ratesClinical careMortality riskCohort characteristicsPatientsDeath ascertainmentCohort
2011
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher H, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan M. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals Of Internal Medicine 2011, 154: 509-15. PMID: 21502648, PMCID: PMC3610527, DOI: 10.7326/0003-4819-154-8-201104190-00001.Peer-Reviewed Original ResearchConceptsCD4 cell countCombined end pointHazard ratioCell countCells/LAntiretroviral therapyCells/L.CD4 cell count thresholdBaseline CD4 cell countEnd pointVeterans Health Administration systemInitiation of cARTThreshold CD4 countCorresponding hazard ratiosMortality hazard ratioAIDS-free survivalProspective observational dataHIV-CAUSAL CollaborationMost clinical guidelinesHealth Administration systemUse of CD4Marginal structural modelsCell count thresholdCART initiationDynamic marginal structural models
2010
HIV and Aging: Time for a New Paradigm
Justice A. HIV and Aging: Time for a New Paradigm. Current HIV/AIDS Reports 2010, 7: 69-76. PMID: 20425560, DOI: 10.1007/s11904-010-0041-9.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAgingAnti-HIV AgentsClinical Trials as TopicComorbidityHealth BehaviorHIV InfectionsHumansMiddle AgedConceptsHIV infectionNon-AIDS diseasesCombination antiretroviral therapyPopulation of patientsCause of morbidityComplex chronic diseaseSpectrum of diseaseProlong life expectancyAntiretroviral therapyCD4 countHIV RNAViral suppressionFunctional statusChronic diseasesPatient riskOptimal managementHIVInfectionLife expectancyDiseaseMorbidityMortalityAIDSRiskPatientsEvaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value?
Braithwaite RS, Fiellin DA, Nucifora K, Bryant K, Roberts M, Kim N, Justice AC. Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value? Value In Health 2010, 13: 535-542. PMID: 20345544, PMCID: PMC3032536, DOI: 10.1111/j.1524-4733.2010.00714.x.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionNonadherent patientsAdherence interventionsRelative riskRisk factorsAntiretroviral therapy adherence interventionsEffect sizeNonadherence risk factorsBehavioral risk factorsHIV careAntiretroviral adherencePatientsNonadherenceSocietal perspectiveIncremental costIntervention costsSmall effect sizesLife expectancyInterventionRisk reductionPlausible effect sizesHIV/AIDS, comorbidity, and alcohol: can we make a difference?
Justice A, Sullivan L, Fiellin D, . HIV/AIDS, comorbidity, and alcohol: can we make a difference? Alcohol Research 2010, 33: 258-66. PMID: 23584067, PMCID: PMC3711181.BooksMeSH KeywordsAcquired Immunodeficiency SyndromeAlcohol DrinkingAnimalsComorbidityHIV InfectionsHumansMulticenter Studies as TopicConceptsVeterans Aging Cohort StudyHIV infectionLong-term HIV infectionAlcohol useAging Cohort StudyHIV/AIDSAssociated comorbidityCohort studyHIV outcomesMedical managementIntervention trialsAlcohol consumptionHealth outcomesAlcohol treatmentMultisite studyComorbiditiesHIVInfectionOutcomesTreatmentAIDSDiseaseTrialsImportant role
2009
Commentary: Treated HIV infection is a chronic disease: the case against cause of death analyses
Justice AC. Commentary: Treated HIV infection is a chronic disease: the case against cause of death analyses. International Journal Of Epidemiology 2009, 39: 146-148. PMID: 19900973, PMCID: PMC3119389, DOI: 10.1093/ije/dyp342.Peer-Reviewed Original ResearchAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsCause of DeathComorbidityHealth BehaviorHIV InfectionsHumansRisk FactorsSex FactorsSocioeconomic FactorsMortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal Of Epidemiology 2009, 38: 1624-1633. PMID: 19820106, PMCID: PMC3119390, DOI: 10.1093/ije/dyp306.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCause of DeathCD4 Lymphocyte CountCohort StudiesFemaleHIVHIV InfectionsHomosexuality, MaleHumansMaleMortalityPrevalenceProspective StudiesRisk FactorsSubstance Abuse, IntravenousViral LoadVirus ReplicationConceptsCD4 cell countAntiretroviral therapyCells/microLGeneral populationCell countEligible patientsExcess mortalityCopies/Start of ARTViral replicationART Cohort CollaborationCorresponding general populationMortality of HIVPotent antiretroviral therapyCombination antiretroviral therapyPercentage of patientsProspective cohort studyInjection drug useViral load measurementsNumber of deathsCohort CollaborationCohort studyMedian ageViral loadClinical stageVariable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal
Mocroft A, Sterne J, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. Clinical Infectious Diseases 2009, 48: 1138-1151. PMID: 19275498, PMCID: PMC3032444, DOI: 10.1086/597468.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCohort StudiesDrug Therapy, CombinationFemaleHumansLymphoma, AIDS-RelatedMalePrognosisProportional Hazards ModelsConceptsCombination antiretroviral therapyMortality hazard ratioAntiretroviral therapyHazard ratioCombination antiretroviral therapy eraClinical end point trialsAntiretroviral therapy eraHIV transmission groupEnd point trialHIV RNA loadPneumocystis jiroveci pneumoniaProgressive multifocal leukoencephalopathyMortality of AIDSProportional hazards modelCommon ADEsMedian followTherapy eraJiroveci pneumoniaMultifocal leukoencephalopathyEsophageal candidiasisImmunodeficiency syndromeHodgkin's lymphomaRNA loadAntiretroviral drugsKaposi's sarcoma
2007
Delayed Presentation for Human Immunodeficiency Virus (HIV) Care Among Veterans
Gandhi NR, Skanderson M, Gordon KS, Concato J, Justice AC. Delayed Presentation for Human Immunodeficiency Virus (HIV) Care Among Veterans. Medical Care 2007, 45: 1105-1109. PMID: 18049352, PMCID: PMC3460382, DOI: 10.1097/mlr.0b013e3181271476.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeCD4 Lymphocyte CountFemaleHealth ServicesHealth Services AccessibilityHIV InfectionsHumansMaleMiddle AgedRetrospective StudiesUnited StatesVeteransConceptsHuman immunodeficiency virusVeterans Health AdministrationHIV presentationHIV careClinical triggersVA healthcareHuman immunodeficiency virus (HIV) careImmune deficiency syndrome diagnosisHIV-positive patientsHalf of patientsRetrospective observational studyCells/Immune deficiency syndromeHalf of veteransVA Medical CenterYear of presentationAntiretroviral therapyCD4 countHIV screeningMedian durationHIV infectionPhysician visitsImmunodeficiency virusDeficiency syndromeObservational studyPrognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal Of Epidemiology 2007, 36: 294-301. PMID: 17213214, PMCID: PMC2820873, DOI: 10.1093/ije/dyl286.Peer-Reviewed Original ResearchAcquired Immunodeficiency SyndromeCanadaCohort StudiesFemaleHumansMaleResearchResearch DesignUnited States